Table 4.

Ongoing MEK inhibitors’ clinical trials in NSCLC

Trial NCT number	Intervention	Cancer type	Phase	Status
03170206	Binimetinib + Palbociclib	KRAS-mutant NSCLC	I/II	Recruiting
01859026	Erlotinib + Binimetinib	KRAS- or EGFR-mutant NSCLC	I/IB	Active, not recruiting
02185690	Carboplatin + Pemetrexed + Binimetinib	NSCLC	I	Active, not recruiting
02964689	Cisplatin + Pemetrexed + Binimetinib	KRAS-mutant NSCLC	I	Active, not recruiting
03581487	Durvalumab + Selumetinib + Tremelimumab	NSCLC	I/II	Recruiting
03991819	Binimetinib + Pembrolizumab	NSCLC	I	Active, not recruiting
01586624	Selumetinib + Vandetanib	NSCLC	I	Active, not recruiting
04526782	Encorafenib + Binimetinib + Docetaxel	BRAF V600E-mutant NSCLC	II	Not yet recruiting
01336634	Dabrafenib + Trametinib	BRAF V600E-mutant NSCLC	II	Active, not recruiting
04005144	Brigatinib + Binimetinib	ALK or ROS1 rearranged NSCLC	I	Recruiting
03087448	Ceritinib + Trametinib	ALK-positive NSCLC	I/II	Recruiting
01933932	Selumetinib + Docetaxel	KRAS-mutant NSCLC	III	Active, not recruiting
03600701	Atezolizumab + Cobimetinib	NSCLC	II	Recruiting
03202940	Alectinib + Cobimetinib	ALK rearranged NSCLC	IB/II	Recruiting
02642042	Trametinib + Docetaxel	KRAS-mutant stage IV NSCLC	II	Active, not recruiting
03299088	Pembrolizumab + Trametinib	KRAS-mutant NSCLC	I	Recruiting
03516214	EGF816 + Trametinib	EGFR-mutant NSCLC	I	Recruiting
03225664	Trametinib + Pembrolizumab	NSCLC	I/II	Recruiting
01750281	Selumetinib + Docetaxel	NSCLC	II	Active, not recruiting
02664935	National Lung Matrix Trial: AZD4547/Vistusertib/Palbociclib/ Crizotinib/ Selumetinib/Docetaxel/AZD5363/ Osimertinib/ Durvalumab/ Sitravatinib/AZD6738	NSCLC	II	Recruiting
03990077	HL-085 + Docetaxel	KRAS-mutant NSCLC	I	Not yet recruiting
01912625	Trametinib + Carboplatin + Paclitaxel + Radiation Therapy	NSCLC	I	Active, not recruiting

Data source: www.clinicaltrials.gov, cutoff data: October 24, 2020